Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline PakistanKAR:GLAXO 93 3-Year EBITDA Growth Rate is 44.60% as of Mar. 2026, which is 472% above its 10-year median of 7.80. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨322.73 (Fairly Valued). The stock has 1 warning sign investors should review. Among 809 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 87.27% on this metric.
During the past 12 months, GlaxoSmithKline Pakistan's average EBITDA Per Share Growth Rate was 31.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GlaxoSmithKline Pakistan was 44.60% per year. The lowest was -18.80% per year. And the median was 7.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GlaxoSmithKline Pakistan 3-Year EBITDA Growth Rate Related Terms
KAR:GLAXO vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.60% mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a 3-Year EBITDA Growth Rate of 44.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pakistan and its competitors. This is 472% above median its historical median of 7.80. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #103 out of 809 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is GlaxoSmithKline Pakistan's 3-Year EBITDA Growth Rate too high?
GlaxoSmithKline Pakistan's current 3-Year EBITDA Growth Rate of 44.60% is 472% above median its 10-year median of 7.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. GlaxoSmithKline Pakistan's value of 44.60% is 401.1% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #103 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #103 out of 809 companies for 3-Year EBITDA Growth Rate. This places GlaxoSmithKline Pakistan in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. GlaxoSmithKline Pakistan's value of 44.60% is 401.1% above this benchmark. While the company's 10-year median is 7.80 vs. the industry median of 8.90, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current 3-Year EBITDA Growth Rate of 44.60% is 401.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current 3-Year EBITDA Growth Rate is 44.60%, which is 472% above median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨322.73, compared to a current price of ₨345.21 — trading 7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 44.60%, which is 472% above median its 10-year median of 7.80 and 401.1% above the Drug Manufacturers industry median of 8.90. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current 3-Year EBITDA Growth Rate is 44.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨345.21 is trading 7% above its estimated GF Value™ of ₨322.73.
GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.
Key valuation signals for KAR:GLAXO:
3-Year EBITDA Growth Rate: 44.60% (472% above median its 10-year median of 7.80)
GF Value™: ₨322.73 vs. price of ₨345.21 (7% above fair value)
Industry Position: 401.1% above the Drug Manufacturers median (#103 of 809)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score
Get the complete analysis for KAR:GLAXO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
